Opexa Therapeutics (OPXA) Triggers Milestone Payment Under Recently Announced Stem Cell Agreement
Opexa Therapeutics (NASDAQ: OPXA) announced that it has achieved its first technology transfer milestone in connection with the company's recently announced exclusive stem cell agreement with Novartis, one of the world's largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.
Opexa recently announced that it entered into an exclusive agreement with Novartis for the further development of Opexa's novel stem cell technology. Under the terms of the agreement, Opexa received an upfront cash payment of $3 million and was entitled to an additional $1 million as a technology transfer fee to be paid over the course of a six month period.
Opexa recently announced that it entered into an exclusive agreement with Novartis for the further development of Opexa's novel stem cell technology. Under the terms of the agreement, Opexa received an upfront cash payment of $3 million and was entitled to an additional $1 million as a technology transfer fee to be paid over the course of a six month period.
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- PDI, Inc. (PDII) Enters New $57M PCP Targeting Contract
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
